Screener / SEC EDGAR /CIK 0001321732 /10-K filed Feb 25, 2026, compared with Feb 18, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Medical Instruments

Penumbra Inc PEN

Compare with peers Embed
SEC comment letters, last 20 years

4 reviews of PEN's filings by SEC staff

UPLOAD and CORRESP
Reviews 4 latest letter Sep 5, 2024
Questions asked 60 each answered in the company's own letter
No closing letter 1 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 9 UPLOAD
  2. 2. Questions in them 60 numbered comments
  3. 3. Company replies 4 CORRESP
  4. 4. Reviews closed 3 of 4 closing letter

Half the closed reviews took 31 days or less from the first letter to the closing letter.

Form 10-K

2024-09-05 to 2024-10-28 · 4 questions · 2 letters from the SEC, 2 from the company
Review closed 2024-10-28
InventoryNon-GAAP measuresGoodwill and impairmentRevenue
Note 4. Impairment of Immersive Healthcare Asset Group, page 12
SEC asked (1)
We note you reported impairment losses on inventory, finite-lived intangibles, and property and equipment for your Immersive Healthcare business since the company made the strategic decision to explore its alternative avenue during the three months ended June 30, 2024.
Rest of the question

Please provide us an analysis of your timeline for making these strategic moves and your considerations for meeting the criteria to report your Immersive Healthcare business as held for sale under ASC 360-10-45 as of December 31, 2023 and June 30, 2024. In that regard, we also note that you began to classify your end markets based on the type of procedure being performed, and therefore divided Immersive Healthcare as a separate market/business beginning with the three months ended December 31, 2023.

PEN answered
1:

We acknowledge the Staff’s comment to provide an analysis of the timeline which led to the decision to explore alternative avenues for our Immersive Healthcare (“IH”) business and our considerations of whether the IH business should be reported as held for sale under ASC 360-10-45 as of December 31, 2023 or June 30, 2024.

During the second quarter of 2024, the Company received feedback from a key customer.
Rest of the answer

These conversations in the second quarter of 2024, and not earlier, underscored that a pathway to grow the IH business would divert our focus from helping as many patients in our core interventional business (consisting of our thrombectomy and embolization and access businesses, excluding the IH business) and Computer Assisted Vacuum Thrombectomy (“CAVT”) technology. As such, management contacted a third-party advisor to explore external interest in the IH business during the second quarter of 2024. The advisor approached several companies, but the process did not identify a suitable buyer, and feedback was provided in June 2024 that while the technology was viable, the go-to-market strategy would need to change. The Company considered whether this exploratory search to gauge external interest triggered asset held for sale accounting under ASC 360-10-45, noting that such classification requires all six criteria listed under ASC 360-10-45-9 to be met. The Company concluded that it did not meet all of the criteria required to classify its IH business as held for sale per ASC 360-10-45-9. For example, at least the following criteria were not met as of June 30, 2024 (or in prior periods):

Criterion Company Assessment

ASC 360-10-45-9(a): Management, having the authority to approve the action, commits to a plan to sell the asset (disposal group).

Assessment: The Company would be required to receive approval from its Board of Directors in order to sell the IH business. Management has the autonomy to explore market interest from prospective buyers and engaged a third party advisor in the second quarter of 2024, however this action did not require, nor was presented to, the Board of Directors for approval. If a suitable buyer was identified in this process, the Company would have been required to obtain approval from its Board of Directors in order to sell the IH business. As a result, the Company lacked the formal approval required to commit to a plan to sell. The Company concluded that this criterion was not met as of June 30, 2024 (or in prior periods).

ASC 360-10-45-9(d): The sale of the asset (disposal group) is probable, and transfer of the asset (disposal group) is expected to qualify for recognition as a completed sale, within one year, except as permitted by paragraph 360-10-45-11. (See Example 8 [paragraph 360-10-55-43], which illustrates when that criterion would be met.) The term probable refers to a future sale that is likely to occur.

Assessment: Based on the feedback provided in June 2024 from our third party advisor that no buyers for the IH business were identified, the Company concluded that it was not “probable” that a sale would be completed within one year as required by ASC 360-10-45-9(d). Additionally, the Company began assessing its strategic alternatives for the IH business during the second quarter of 2024, but had not reached a definitive conclusion whether it would continue to develop, sell or otherwise dispose of the IH business (as discussed below). As such, the Company concluded that this criterion was not met as of June 30, 2024 (or in prior periods).

After taking into consideration the feedback received from our advisor in June 2024 about the IH business, the Company began evaluating three potential courses of action: (1) increase its time and focus to develop the market for the IH business, (2) continue to search for a buyer and try to sell the business, or (3) otherwise dispose of the IH business (i.e., wind-down the business) to prioritize its investment in its core interventional business. Although no definitive decision about the future of the IH business was reached as of the filing date of the Company’s Form 10-Q for the fiscal quarter ended June 30, 2024, the Company concluded that it was more likely than not that the IH business would be sold or otherwise disposed of significantly before the end of the previously estimated useful lives of the long-lived assets that support the business (the “IH asset group”). As such, the Company determined that a triggering event had occurred and tested the long-lived asset group for impairment as a held and used asset group in accordance with ASC 360-10-35-21 (f). The Company performed a probability-weighted estimation of future cash flows for its IH asset group and determined the asset group was not recoverable. In the third fiscal quarter of 2024 and subsequent to filing the Company’s Form 10-Q for the second fiscal quarter of 2024, the Company made the decision to dispose of the IH business and filed a Worker Adjustment and Retraining Notification Act (“WARN Act”) notice with the California Employment Development Department on August 20, 2024. This filing supports the Company’s probability-weighted approach utilized in its impairment assessment with respect to the second quarter of 2024 and the weighting placed on the potential outcome that the IH business would be disposed of significantly before the end of the previously estimated useful lives of the IH asset group.

In the periods prior to the quarter ending June 30, 2024, the Company expected to continue to develop and pursue this line of business, and accordingly, the IH business did not meet any of the required criteria for asset held for sale accounting under ASC 360-10-45-9 nor have a triggering event for which to assess impairment.

We also acknowledge the Staff’s comment regarding the change made during the fourth fiscal quarter of 2023 to realign our end markets and present our product revenue categories based on the type of medical procedures being performed. The Company made this change to provide investors with more meaningful information to understand the performance of its normal operations (the core interventional business which excludes the IH business) and strategic initiatives, in particular as we continue to develop and introduce our CAVT technology into products used in thrombectomy procedures. The Company respectfully advises the Staff that its IH business has operated as an immaterial component of the consolidated Company since its inception, representing less than [*]% and [*]% of consolidated revenue and consolidated cost of revenue, respectively, in 2023, as its market was an undeveloped field within healthcare. The IH business has been discussed as a separate market in the Company’s Annual Reports on Form 10-K beginning with the fiscal year ended December 31, 2021, as it addresses clinical needs that include immersive applications for patients undergoing rehabilitation related to diseases, injuries, or illnesses, as well as applications designed to address mental well-being and cognition, which differ from the clinical applications addressed by the Company’s core interventional products.

Read in the reply
In its next report

First report after the company's reply of Sep 17, 2024: 10-Q filed Oct 30, 2024 ↗, against the 10-Q filed Jul 30, 2024 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Exhibit 99.1, page 1
SEC asked (2)
Within the header of your earnings release you discussed the non-GAAP measures Adjusted EBITDA and adjusted EBITDA margin without also discussing the most comparable GAAP measure of net (loss) income and net (loss) income margin.
Rest of the question

Please revise your header and presentations in future filings accordingly to comply with Item 10(e)(1)(i)(A) of Regulation S-K and Question 102.10(a) of the Division's Compliance & Disclosure Interpretations (“C&DIs”) on Non-GAAP Financial Measures.

PEN answered
2:

We respectfully acknowledge the Staff’s Comment and inform the Staff that we will revise our Adjusted EBITDA and adjusted EBITDA margin header and presentation to include the most comparable GAAP measure of net (loss) income and net (loss) income margin in future filings accordingly to comply with Item 10(e)(1)(i)(A) of Regulation S-K and Question 102.10(a) of the Division's Compliance & Disclosure Interpretations (“C&DIs”) on Non-GAAP Financial Measures.
Rest of the answer

For illustrative purposes, we believe the underlined revisions to our header below is responsive to the Staff’s comment and we will include it in future filings when the non-GAAP measures Adjusted EBITDA and adjusted EBITDA margin are presented or when applicable:

•Net loss of $60.2 million, or net loss margin of (20.1)%, and Adjusted EBITDA of $46.3 million, or adjusted EBITDA margin of 15.5%, in the second quarter of 2024.

Read in the reply
In its next report

First report after the company's reply of Sep 17, 2024: 10-Q filed Oct 30, 2024 ↗, against the 10-Q filed Jul 30, 2024 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Exhibit 99.1, page 1
SEC asked (3)
We note that several of your non-GAAP performance measures include an adjustment of $33.4 million for an inventory write-down of Immersive Healthcare asset group and such charge was recorded as cost of revenue. With reference to ASC 420-10-S99-3, please tell us your consideration of the guidance in Question 100.01 of the Division's Compliance and Disclosure Interpretations ("C&DIs") on Non-GAAP Financial Measures.
Rest of the question

In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

PEN answered
3:

We acknowledge the Staff’s comment and respectfully advise that management believes we complied with ASC 420-10-S99-3. As noted in our response to the Staff’s comment No. 1 above, our IH business did not meet the asset held for sale criteria as of June 30, 2024 (or in prior periods). In addition, while the inventory markdown directly resulted from the Company’s assessment that it was more likely than not that it would sell or dispose of the IH business, we reflected the inventory write-down charge as a component of cost of revenue in the Consolidated Statement of Operations in accordance
Rest of the answer

with ASC 420-10-S99-3.

The Company respectfully believes that its $33.4 million adjustment included in its non-GAAP performance measures for an inventory write-down in its IH asset group meets the requirements of Question 100.01 of the C&DI on Non-GAAP Financial Measures as it does not represent “usual, recurring, non-cash operating costs required to run a registrant’s business.” The Company acknowledges that ASC 420-10-S99-3 states, “…the staff believes that decisions about the timing, method, and pricing of dispositions of inventory generally are considered to be normal, recurring activities integral to the management of the ongoing business.” As a general matter, we have not previously included any adjustments for inventory write-offs related to the normal operations of our business in our non-GAAP financial measures, nor do we plan to do so in the future.

As noted in our response to the Staff’s comment No. 1 above, the Company respectfully advises that its IH business has operated as an immaterial component of the consolidated Company since its inception that is separate from our normal, recurring, cash operating expenses necessary to operate our core interventional business. As such and when considering the guidance in Question 100.01, the Company deems the inventory write-down charge to be directly associated with its assessment that it was more likely than not that it would sell or dispose of the IH asset group and not a part of the normal operations of our core interventional business. The Company believes non-GAAP financial measures provide management as well as investors with useful information to evaluate the performance of our business, because such measures, when viewed together with our financial results computed in accordance with GAAP, provide a more complete understanding of the factors and trends affecting our historical financial performance and projected future results. The Company believes the inclusion of this one-time charge related to the IH business in its non-GAAP measures would significantly distort the usefulness of non-GAAP gross margin and could lead investors to draw incorrect conclusions about the ongoing profitability of the Company’s normal core interventional operations, in addition to impacting the comparability of these financial metrics in future periods. For instance, the $33.4 million charge reduced GAAP gross margin by over 10% for the three months ended June 30, 2024. This substantial impact starkly contrasts with the immaterial effect the IH business has on our normal operations from our core interventional business in periods without this one-time charge. Historically, the operations of the IH business had no meaningful impact on the Company’s gross margin due to the immaterial nature of the IH business and accordingly do not impact investors’ ability to assess our operating performance. To illustrate the immaterial effect of the IH business on our normal operations, we reported a non-GAAP gross margin of 65.5% for the three months ended June 30, 2024, which includes an adjustment to exclude the $33.4 million inventory write-down (but does not exclude the remaining operations of our IH business during the period). If we excluded the operations of our IH business in their entirety from our consolidated results for the three months ended June 30, 2024, the adjusted gross margin would have only been reduced by an additional [*]% to [*]%. As a result, the Company believes the exclusion of these charges does not result in misleading non-GAAP financial measures and instead provides relevant information to understand and measure the Company’s normal operating performance from its core interventional business.

Read in the reply
In its next report

First report after the company's reply of Sep 17, 2024: 10-Q filed Oct 30, 2024 ↗, against the 10-Q filed Jul 30, 2024 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

After reviewing your response to this letter, we may have additional comments. Exhibit 99.1, page 1
SEC asked
We have reviewed your response to comment 3 and note your views regarding inventory write-downs related to Immersive Healthcare ("IH") Asset Group. Inventory write-downs directly resulted from the Company’s assessment that it was more likely than not that it would sell or dispose of the IH business do not appear to be outside the normal course of operations.
Rest of the question

Please refer to Question 100.01 of Non- GAAP Compliance & Disclosure Interpretations. In future filings, please discontinue making this adjustment to your non-GAAP measures.

PEN answered
1:

The Company acknowledges the Staff’s comment and confirms that it will no longer exclude inventory write-downs from its non-GAAP financial measures in future filings.
Read in the reply
In its next report

First report after the company's reply of Oct 25, 2024: 10-Q filed Oct 30, 2024 ↗, against the 10-Q filed Jul 30, 2024 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2024-10-28

Form 10-K

2020-12-03 to 2020-12-21 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2020-12-21
Risk factorsLegal and contingenciesDerivatives and hedging
SEC asked
We note that your forum selection provision in your bylaws identifies a state court located within the State of Delaware (or, if no state court located within the State of Delaware has jurisdiction, the federal district court for the District of Delaware) as the exclusive forum for certain litigation, including any “derivative action.” Please revise your risk factor to make this mechanism clear, and disclose whether
Rest of the question

this provision applies to actions arising under the Securities Act or Exchange Act. If so, please also state that there is uncertainty as to whether a court would enforce such provision. If the provision applies to Securities Act claims, please also state that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. In that regard, we note that Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder.

PEN answered
The Company acknowledges the Staff’s comment and respectfully advises the Staff that it will expand its disclosure in future filings to state that the Company’s bylaws include a forum selection provision which states that a state court located within the State of Delaware (or, if no state court located within the State of Delaware has jurisdiction, the federal district court for the District of Delaware) is the exclusive forum for certain litigation, including any derivative action.
Rest of the answer

In addition, in response to the Staff’s comment, the Company will revise its disclosure in future filings to clarify that the forum selection provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act or the Securities Act or, in each case, the rules and regulations thereunder, or for any other claim for which the U.S. federal courts have exclusive jurisdiction.

Read in the reply

Also in this review: closing letter, 2020-12-21

Form 10-K for the Fiscal Year Ended December 31, 2017

2018-06-08 to 2018-07-09 · 3 questions · 1 letter from the SEC, 1 from the company
Review closed 2018-07-09
AcquisitionsControls
Note 3. Investments and Fair Value of Financial Instruments · Non-Marketable Equity Investments, page 72
SEC asked (1)
Please tell us how you considered the provisions of Rule 3-09 of Regulation S-X in your determination not to include additional financial statements for your equity method investee MVI Health, Inc. that you formed during fiscal 2017. In your response, please provide us with your calculations of the significance for this equity method investee.
PEN answered
The Company respectfully acknowledges the Staff’s comments on the significant subsidiary test with respect to our equity method investee, MVI Health Inc. (“MVI”). Pursuant to the requirements of Rule 3-09(a) of Regulation S-X with respect to a 50 percent-or-less-owned person, the Company performed significance tests on MVI for the year ended December 31, 2017 as outlined in Rule 1-02(w) of Regulation S-X in the following table below:

Rule 1-02(w) Test - Pursuant to Rule 3-09

(in USD and thousands, except
Rest of the answer

percentages)

Numerator

Denominator

Significance

Investment(1)

3,859

476,667

0.8

%

Income(2)

1,430

1,928

74.2

(1) In accordance with the instructions in Rule 1-02(w)(1) of Regulation S-X, the numerator in the investment test represents the carrying amount of the Company’s investment in MVI as of December 31, 2017, and the denominator represents the Company’s total assets as of December 31, 2017.

(2) Pursuant to Section 2410.3 of the Division of Corporation Finance's Financial Reporting Manual (“FRM”), the numerator represents the Company’s proportionate share of MVI’s loss before income taxes for the year ended December 31, 2017. Pursuant to the instructions in Section 2410.5 of the FRM, the Company determined that it qualified for income averaging. Accordingly, the denominator in the income test represents the Company’s average income before income taxes for the last five fiscal years with a value of zero assigned in fiscal 2016 and 2013, as the Company incurred a loss before income taxes in those years, and excludes MVI’s loss before taxes in 2017 pursuant to computational note 2 to Rule 1-02(w) of Regulation S-X.

The Company acknowledges that strict adherence to the income test guidance would have required the filing of separate audited financial statements for MVI, pursuant to Rule 3-09 of Regulation S-X for the year ended December 31, 2017. However, considering the disaggregated disclosures about MVI’s financial position and results of operations that are contained in our consolidated financial statements pursuant to Rule 4-08(g) of Regulation S-X (“Rule 4-08”) the Company does not believe the separate financial statements of MVI are significant to an investor’s understanding of the Company’s financial position or results of operations for the year ended December 31, 2017. Accordingly, the Company has submitted a letter to the Division of Corporation Finance’s Office of the Chief Accountant requesting a waiver to the requirements of Rule 3-09 of Regulation S-X, given the relatively insignificant financial results of MVI relative to the Company.

Read in the reply
In its next report

First report after the company's reply of Jun 21, 2018: 10-Q filed Aug 7, 2018 ↗, against the 10-Q filed May 8, 2018 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Fair Value of Financial Instruments, page 73
SEC asked (2)
With respect to the contingent consideration recorded for the Crossmed acquisition and the technology licensing agreement disclosed on page 74, in future filings please revise this note to also disclose quantitative information about the significant unobservable inputs underlying the level 3 fair value measurements. Refer to ASC 820-10-50-2bbb.
PEN answered
The Company respectfully acknowledges the Staff’s comment and will revise future filings accordingly starting with Form 10-Q for the quarterly period ending June 30, 2018.
Read in the reply
In its next report

First report after the company's reply of Jun 21, 2018: 10-Q filed Aug 7, 2018 ↗, against the 10-Q filed May 8, 2018 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Exhibits 31.1 and 31.2
SEC asked (3)
We note the certifications provided do not include the introductory language in paragraph 4 referring to internal control over financial reporting although you are now beyond the transition period that allows for these omissions. Please amend the filing to provide revised certifications.
Rest of the question

You may file an abbreviated amendment that is limited to the cover page, explanatory note, signature page and paragraphs 1, 2, 4 and 5 of the certification. Refer to Exchange Act Rule 13a-14(a) and Item 601(b)(31) of Regulation S-K.

PEN answered
The Company respectfully acknowledges to the Staff that it inadvertently omitted the referenced introductory language in paragraph 4 from the certifications filed as Exhibit 31.1 and 31.2 to Form 10-Q for the quarterly period ended March 31, 2018, and filed on May 8, 2018 (the “Quarterly Report”). As requested by the Staff, the Company will file an abbreviated amendment to the Quarterly Report, which includes the introductory language in paragraph 4 as indicated by the Staff.
Rest of the answer

The Company further acknowledges that the certifications, in the form to be filed with the amendment to the Quarterly Report, were each true and correct as of the original filing date of the Quarterly Report.

Read in the reply
In its next report

First report after the company's reply of Jun 21, 2018: 10-Q filed Aug 7, 2018 ↗, against the 10-Q filed May 8, 2018 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2018-07-09

Form S-1

2015-07-06 to 2015-09-03 · 52 questions · 5 letters from the SEC, 0 from the company
No closing letter
Results discussion (MD&A)RevenueRisk factorsReserves and insuranceInventory
SEC letter of Jul 6, 2015 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
Prospectus Summary, page 1
SEC asked (1)
Please provide us objective support for your statements regarding “one of the largest independent companies focused on the neuro market” and “significantly lower overall cost.” Ensure that your response is consistent with your disclosure on page 12 regarding competitors offering greater discounts and other incentives.
PEN answered

No reply letter found.

Prospectus Summary, page 1
SEC asked (2)
We note your use of highly technical terms such as “ischemic,” “hemorrhagic,” “thrombectomy,” and “embolization.” Please replace highly technical terms currently in the forepart of your document with concrete, everyday terms that are understandable to investors who may not be experts in your industry.
PEN answered

No reply letter found.

Implications of Being an Emerging Growth Company, page 5
SEC asked (3)
Please supplementally provide us with copies of all written communications, as defined in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf, present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not they retain copies of the communications.
PEN answered

No reply letter found.

Risk Factors, page 10
SEC asked (4)
Please provide the name of the distributor that accounted for 11.7% of your revenue in 2014 as mentioned on page 19.
PEN answered

No reply letter found.

It is difficult to forecast future performance, page 31
SEC asked (5)
In an appropriate section of your prospectus, please describe the seasonal variations that you mention in the first bullet point of this risk factor. Include disclosure of when the cited major conferences occur.
PEN answered

No reply letter found.

A significant portion of our outstanding shares of common stock, page 34
SEC asked (6)
If the lock-up agreement that you mention here can be waived, please revise to clarify the effect of the potential waiver.
PEN answered

No reply letter found.

Use of Proceeds, page 40
SEC asked (7)
Please disclose the approximate amount of proceeds that you currently intend to use for each purpose mentioned in this section. You may reserve the right to change the use of proceeds as described in Instruction 7 to Regulation S-K Item 504. In this regard, please tell us the source and amount of funds to be used for the activities that you mention in the last sentence beginning on page 20.
Rest of the question

If you have no current specific plan for the proceeds, or a significant portion of the proceeds, please say so directly and discuss the principal reasons for this offing.

PEN answered

No reply letter found.

Results of Operations, page 49
SEC asked (8)
We note your general explanations on pages 50 through 52 of why your revenues fluctuated from the three months ended March 31, 2015 as compared to the three months ended March 31, 2014 and from fiscal 2014 as compared to fiscal 2013.
Rest of the question

Please revise Management's Discussion and Analysis to explain and quantify, where possible, if the changes in your revenues during the periods presented were due to changes in prices, volumes or a combination of both items. Please refer to Item 303 and the related instructions in Regulations S-K as well as SEC Interpretive Release No. 33-8350. Also quantify the impact of the introduction of new products during each of the periods presented.

PEN answered

No reply letter found.

Results of Operations, page 49
SEC asked (9)
Please clarify when the “several recently published trial results” that you mention on pages 50 and 52 were published. Also, tell us whether the studies were affiliated with you; include in your response the nature of any such affiliation.
PEN answered

No reply letter found.

Results of Operations, page 49
SEC asked (10)
Please tell us whether all of the products that you identify on page 71 as offered for sale have experienced the same sales trends during the periods presented. For example, we note your disclosure on page 72 that the Benchmark product includes “additional improvements.” It is unclear whether your previous intracranial access products maintained their historic sales level after you began offering a product with
Rest of the question

improvements.

PEN answered

No reply letter found.

Contractual Obligations and Commitments, page 55
SEC asked (11)
Please tell us the authority on which you rely to exclude the contracts mentioned in the last sentence of footnote (3). Also tell us the dollar amount that you have excluded.
PEN answered

No reply letter found.

Business, page 63
SEC asked (12)
Please tell us whether you commissioned any of the market or industry data cited here and elsewhere in your prospectus. Also, please tell us whether you commissioned any of the clinical or other studies cited in your prospectus; address in your response all relationships between you and the studies you cite.
PEN answered

No reply letter found.

Our Products, page 71
SEC asked (13)
Please tell us (1) whether all of the study results that you disclose in your prospectus are statistically significant, and (2) whether you are aware of any studies that reveal any negative results or limitations of your products. Also tell us whether competitive products offer results that are similar to or better than the study results that you disclose for your products.
PEN answered

No reply letter found.

Our Products, page 71
SEC asked (14)
We note your disclosure on page F-21 that you anticipated the first sale of a product in June 2015. Please tell us which product is the subject of that disclosure.
PEN answered

No reply letter found.

Penumbra System Clinical Experience, page 76
SEC asked (15)
Please clarify the meaning of the “Merci” column heading.
PEN answered

No reply letter found.

Intellectual Property, page 87
SEC asked (16)
We note your reference on page 28 to a license to necessary technology. Please tell us the importance to your business of your licenses and the duration and termination provisions of licenses to necessary technology. Also provide us your analysis of whether any such licenses must be filed as an exhibit to your registration statement.
PEN answered

No reply letter found.

Government Regulation, page 87
SEC asked (17)
We note your disclosure on page 84 that you have introduced your products in either the United States, international markets, or both. We also note your disclosure on page 85 that you have clearance to sell “many” of your products in the “majority” of markets worldwide.
Rest of the question

In an appropriate section of your document, please clarify in which jurisdictions the products that you identify on page 71 have received the regulatory clearances necessary for them to be sold.

PEN answered

No reply letter found.

2014 Equity Incentive Plan, page 102
SEC asked (18)
Please describe the material substance of the amendment mentioned in the last sentence of the first paragraph of this section.
PEN answered

No reply letter found.

Certain Relationships and Related Party Transactions, page 109
SEC asked (19)
The criteria that you mention in the first two paragraph of this section do not appear to address all disclosure required by Regulation S-K Item 404. For example, see Instruction 1.a.iii to Item 404. Please revise to provide all required disclosure, including the identity of all related persons that are a party to the Investor Rights Agreement.
PEN answered

No reply letter found.

Certain Relationships and Related Party Transactions, page 109
SEC asked (20)
Please tell us whether the loans mentioned in Note 6 on page F-20 will be repaid before you file this registration statement. See Exchange Act Section 13(k).
PEN answered

No reply letter found.

Description of Capital Stock, page 113
SEC asked (21)
Please tell us the authority on which you rely to qualify your disclosure by reference to “applicable law.”
PEN answered

No reply letter found.

Other Limitations, page 115
SEC asked (22)
Please provide us your analysis of how investors could satisfy the deadline in clause (2) of the last bullet point in this section while also satisfying the “not less than 90” days requirement.
PEN answered

No reply letter found.

Underwriting, page 122
SEC asked (23)
From your disclosure in the last paragraph on page 122, it appears that Parella Weinberg Partners is an underwriter as defined by Section 2(a)(11) of the Securities Act. Please revise or advise. Also, please tell us when your arrangement with Parella was made and the context of the arrangement; provide us a copy of any related agreement.
PEN answered

No reply letter found.

United Kingdom, page 126
SEC asked (24)
Please provide more specific information regarding your past relationships with the underwriters mentioned in the third paragraph of this section. Also, please include this disclosure under a caption that indicates the nature of the information in the disclosure; it is unclear why this disclosure is related to the “United Kingdom” caption.
PEN answered

No reply letter found.

Notes to Consolidated Financial Statements, page F-7 · Note 4. Balance Sheet Components, page F-17
SEC asked (25)
We note your disclosure on pages 10, 15 and throughout the filing that you have consigned inventory maintained at hospitals. Please revise this note to separately present your consigned inventory. Refer to Question 2 of SAB Topic 13(A)(2).
PEN answered

No reply letter found.

Exhibits
SEC asked (26)
Please file Exhibits B and C mentioned in section 1.12 of Exhibit 10.1. Also file the agreement mentioned in the sixth paragraph of Exhibit 10.10 and the related agreements mentioned in the other employment agreements you filed.
PEN answered

No reply letter found.

SEC letter of Jul 24, 2015 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
Prospectus Summary, page 1
SEC asked (1)
We note your response to prior comment 1. If your disclosure regarding “significantly lower overall costs” is supported by objective data regarding only a portion of your products, please revise to clarify the scope of the statement. If the statement applies to all of your products, please provide us additional objective support for that statement.
Rest of the question

Also, if some of your products are less cost effective than alternatives, please balance your disclosure to clarify.

PEN answered

No reply letter found.

Management’s Discussion and Analysis of Financial Condition and Results of Operations, page
SEC asked (2)
We will continue to evaluate your response to prior comment 5 after you add the disclosure mentioned in that response.
PEN answered

No reply letter found.

Management’s Discussion and Analysis of Financial Condition and Results of Operations, page
SEC asked (3)
Please address that part of prior comment 8 that sought disclosure that indicates the extent of the impact of new product introductions during each of the periods presented. See Regulation S-K Item 303(a)(3)(iii).
PEN answered

No reply letter found.

Management’s Discussion and Analysis of Financial Condition and Results of Operations, page
SEC asked (4)
Please disclose the substance of the last two sentences of your response to prior comment 10 in your discussion of the relevant period’s results.
PEN answered

No reply letter found.

Business, page 63
SEC asked (5)
We note your response to prior comment 13. Please ensure that your disclosure makes clear in context the date of the cited studies, such as the ISAT study that you mention on page 67. Also ensure that you make clear which of the cited studies did not involve your products.
PEN answered

No reply letter found.

Business, page 63
SEC asked (6)
Please expand your response to prior comment 13 to tell us whether each of the cited studies generated results that were statistically significant standing alone, not “compared to each other” as mentioned in your response; in this regard, the significance and limitations of the disclosed initial PRISM study results are unclear.
Rest of the question

Also, please tell us whether you are aware of any studies that reveal (1) any negative results or limitations of your products or (2) results from competitive products that are similar to or better than the results from your products disclosed in your prospectus; your response to prior comment 13 appears only to partially address these issues.

PEN answered

No reply letter found.

Government Regulation, page 87
SEC asked (7)
Please revise your disclosure added in response to prior comment 17 to clarify which of the “key products” that you mention on page 71 are the “core products” that you mention on page 85 as having been cleared for sale.
PEN answered

No reply letter found.

Underwriting, page 122
SEC asked (8)
Please expand your response to prior comment 23 to cite with specificity all authority on which you rely to conclude that an entity that engages in the activities mentioned in the paragraph at the bottom of page 122 and in the Perella engagement letter is not directly or indirectly participating in the offering per Section 2(a)(11) of the Securities Act.
PEN answered

No reply letter found.

SEC letter of Aug 12, 2015 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
Overview, page 1
SEC asked (1)
We note your response to prior comment 1 that you are not aware of any study stating, and you have no basis to believe, that your products are less cost effective than alternatives. Please tell us how that response reflects the first table in the ADAPT FAST study and the last page of the PRISM study results.
PEN answered

No reply letter found.

We are subject to periodic inspections by the FDA…page 24
SEC asked (2)
If you have received a notice of inspectional observations or deficiencies, please revise the last sentence of this risk factor caption to clarify. Also, if the FDA could take action without a subsequent inspection, please revise the third sentence of the last paragraph of this risk factor to remove any implication that such action is contingent on a subsequent investigation.
PEN answered

No reply letter found.

Management’s Discussion and Analysis fo Financial Condition and Results of Operations, page
SEC asked (3)
We will continue to evaluate your responses to prior comment 2 and 3 when you provide the disclosure mentioned in those responses.
PEN answered

No reply letter found.

Business, page 63
SEC asked (4)
We note your response to prior comment 6. Please revise your prospectus disclosure to make clear the significance and limitations of “initial” PRISM study results. Likewise, please ensure that any limitations on the other studies that you disclose are clear so that investors have sufficient information to evaluate the significance of the data presented; for example, if your table on page 76 compares data that is
Rest of the question

statistically significant with data whose statistical significance was not assessed, ensure that the relevance of that distinction in clear from your disclosure.

PEN answered

No reply letter found.

Business, page 63
SEC asked (5)
We note your response to prior comment 6 that you are not aware of any study that reveals any negative results or limitations of your products or results from competitive products that are similar to or better than the results of your products disclosed in your prospectus. Please tell us how that response reflects the “traditional Penumbra System” results from the ADAPT FAST study.
PEN answered

No reply letter found.

Sales and Marketing, page 85
SEC asked (6)
From your response to prior comment 7, it appears that the Indigo system has not been cleared for sale in any of your major markets. If so, please tell us where the launch of that product mentioned on page 50 occurred.
PEN answered

No reply letter found.

Sales and Marketing, page 85
SEC asked (7)
Please clarify your disclosure that your Coil 400 is used for peripheral embolization in Japan. Do you mean that the product is being used in a manner that has not been approved?
PEN answered

No reply letter found.

Underwriting, page 122
SEC asked (8)
We note your response to prior comment 8. Although your prospectus need not specifically identify Perella Weinberg as an underwriter in this instance, your prospectus should not affirmatively disclaim underwriter status. Please revise your disclosure accordingly. Also, please more fully describe in your prospectus the services provided or to be provided by Perella Weinberg.
Rest of the question

File the related agreement as an exhibit to your registration statement, and tell us about any other relationships Perella Weinberg has or had with the registrant.

PEN answered

No reply letter found.

SEC letter of Aug 28, 2015 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
Overview, page 1
SEC asked (1)
We note your response to prior comment 1. If the cost of your device itself is higher than available alternatives, please clarify your disclosure about cost savings. Also, if you continue to offer previous generation products that now have more cost-effective alternatives, please revise your disclosure to clarify.
PEN answered

No reply letter found.

Capitalization, page 42
SEC asked (2)
We note that you present $129,070,000 as your actual historical capitalization as of June 30, 2015. We also note the same amount is recorded in your consolidated balance sheet on page F-3 as total assets as of June 30, 2015. Please revise the filing to present your actual historical capitalization as of June 30, 2015 or tell us why no revisions are necessary.
PEN answered

No reply letter found.

Management’s Discussion and Analysis of Financial Condition and Results of Operation, page
SEC asked (3)
We will continue to evaluate your response to prior comment 3 when you file the subsequent amendment that you mention in that response.
PEN answered

No reply letter found.

Revenue, page 51
SEC asked (4)
Please quantify the extent of the decrease in sales of your neuro embolization products during the period ended June 30, 2015. Also discuss the reasons for the decrease.
PEN answered

No reply letter found.

Business, page 65
SEC asked (5)
We note your response to prior comment 5; however, if you currently derive revenue from products that have been demonstrated by studies to have limitations or to have performed at rates lower than alternatives, it is unclear how your disclosure about studies presents a balanced presentation of your products. Please advise or revise your prospectus accordingly.
PEN answered

No reply letter found.

Indigo System, page 86
SEC asked (6)
We note your response to prior comment 4; however, it is unclear how your disclosure added on page 87 addresses the significance and limitations of the initial results. For example, are results based on 38 patients reasonably indicative of results to be expected from a complete study? Why or why not?
PEN answered

No reply letter found.

Underwriting Page 122
SEC asked (7)
We note your response to prior comment 8. Please disclose in your prospectus your prior relationships with Perella Weinberg. Also, it remains unclear why you believe that your agreement with Perella need not be filed as an exhibit if it was not made in the ordinary course of your business; please expand your analysis of the materiality of the agreement to address the nature of the agreement, its significance to this
Rest of the question

offering, and the cost relative to your net loss.

PEN answered

No reply letter found.

SEC letter of Sep 3, 2015 ↗ no reply letter on EDGAR (the company may have answered in an amended filing)
Revenue, page 51
SEC asked (1)
We note your disclosure added in response to prior comment 4. However, because you do not disclose the dollar amount of your sales from your neuro embolization products, the significance of the disclosed 20% decrease in sales is unclear. Therefore, the extent of the increase in sales of your other products is unclear.
Rest of the question

Please revise for clarity regarding the extent of the decrease in sales, and discuss the reasons for the reduced demand.

PEN answered

No reply letter found.

Quarterly Results, page 55
SEC asked (2)
We note your statement that your “revenue and gross profit increased sequentially for all quarters presented.” However, it appears that your gross margins decreased in the quarter ending June 30, 2015 as compared to the quarter ending March 31, 2015. Please revise your disclosure to clarify the reasons for the decrease.
PEN answered

No reply letter found.

Indigo System, page 87
SEC asked (3)
We note your response to prior comment 6 and your reference to initial clinical experience on page 87. Please clarify the significance and limitations of the initial results.
PEN answered

No reply letter found.

Letters without questions

Other letters

UPLOAD and CORRESP
2 other letters: notices that a filing will not be reviewed, requests to declare a registration effective, and the like

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 18 letters filed since 2015-07-06. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/PEN/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.